Aetna stops paying Bextra drug claims

	Tweet

Health insurer Aetna Inc. said on Monday it is not paying any claims for Bextra, a pain reliever that the FDA requested to be removed from the market, for prescriptions as of April 7.

The Hartford-based company said it is contacting more than 33,000 customers who have used Bextra to inform them of the U.S. Food and Drug Administration’s (FDA) decision to ask that Bextra be withdrawn from the market.

Pfizer Inc. agreed to suspend sales of Bextra after U.S. and European regulators said the side effects, including a potentially fatal skin allergy, outweigh the benefits.

Aetna Pharmacy Management has instituted computer system edits that will automatically block Bextra prescriptions from being paid.

Besides the direct communications, Aetna Pharmacy Management will communicate the news concerning Bextra and increased warnings the FDA is requiring of all Cox-2 inhibitors and non-steroidal anti-inflammatory drugs, such as ibuprofen and naproxen, on its corporate and pharmacy Web sites in an attempt to reach all members.

The FDA has been studying the safety of Cox-2 inhibitors since Merck & Co. Inc. voluntarily recalled Vioxx in September 2004 after a clinical study showed an increased risk of cardiovascular problems. 

RELATED STORIES:
Merck sought to reformulate Vioxx in 2000   Painkiller prescribing varies dramatically among family physicians: study   Online info influences teen drug use   Group asks US FDA for ibuprofen warnings   Strong Drugs without the Addiction   Blindness Warning Given to US Viagra Users   FDA warns of allergy risk with Merck antipsychotic   Lawmakers protest morning-after pill ruling   Drug reduces hot flashes in breast cancer patients   Drug abuse effects linger   It Is Easy to Purchase Prescription Drugs and Controlled Substances Through Spam Messages   Anesthesiologists Vulnerable to Drug Abuse

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]